Thursday, June 16, 2016

Lupus News! Anti-interferon antibody - anifrolumab

I love sharing positive news about lupus drugs, trials, or advancements in the treatment of the disease!  Today's news is about the anti-interferon antibody, anifrolumab that has been shown to dramatically reduce disease activity in extrarenal systemic lupus.  Here's some info from the article....

LONDON, United Kingdom — After years of clinical trial failures, an anti-interferon antibody, anifrolumab, has been shown to dramatically reduce disease activity in extrarenal systemic lupus erythematosus.
In a large phase 2 trial, "we saw consistent, good results with anifrolumab across multiple measures of disease activity," said Richard Furie, MD, chief of rheumatology at Northwell Health in Long Island, New York. "I think these results give us more than hope."
"There has been failure after failure after failure in terms of new clinical trials, not just in extrarenal lupus, but also in lupus nephritis," Dr Furie told Medscape Medical News. "There is a great need for safer therapies, for better therapies, and for targeted therapies. And now we have these phase 2 study results that are very robust."
Click here to read the rest of the article. 

No comments:

Post a Comment